Cocrystal Pharma, Inc.

What's your position on ?
Why are you ish?
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Nov. 25, 2014, 12:59 PM
    • The merger between Cocrystal Pharma (OTCQB:COCP +10.9%) and RFS Pharma, LLC has closed. The shareholders of each company will each own ~50% of combined entity.
    • The merged organization will have a broad pipeline of products in hepatitis, influenza, rhinovirus, dengue fever and norovirus.
    • Dr. Gary Wilcox will be CEO and Co-Chairman of the new firm. RFS Founder and Chairman Dr. Raymond F. Schinazi will be the other Co-Chairman.
    | Nov. 25, 2014, 12:59 PM
  • Aug. 15, 2014, 8:17 AM
    • Cocrystal Pharma (OTCQB:COCP) Q2 results: Revenues: $0; Operating Expenses: $1.4M (+34.5%); Net Income: $4.7M (change in value of derivative liabilities); EPS: $0.01; Quick Assets: $9.8M (+880.0%); Cash Burn (1H): ($3.1M) (-61.6%).
    • No financial guidance given.
    | Aug. 15, 2014, 8:17 AM
  • May 16, 2014, 9:07 AM
    • Cocrystal Pharma (COCP) increases its cash position to $9.88M after raising $2.75M from eight investors including OPKO Health Chairman Philip Frost. Proceeds will be used to fund R&D and well as working capital.
    • IND for Hep C candidate expected to be filed by year end.
    | May 16, 2014, 9:07 AM
Company Description
Cocrystal is a biotechnology company which develops novel medicines for use in the treatment of human viral diseases. Cocrystal has developed proprietary structure-based drug design technology and antiviral nucleoside chemistry to create first-in-class and best-in-class antiviral drug... More